SBPH Spring Bank Pharmaceuticals Inc.

1.63
+0.04  (+3%)
Previous Close 1.59
Open 1.58
Price To Book 0.99
Market Cap 27,864,588
Shares 17,094,839
Volume 91,019
Short Ratio
Av. Daily Volume 150,257
Stock charts supplied by TradingView

NewsSee all news

  1. Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

    HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and

  2. Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results

    Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche's Tecentriq® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I and STING agonists

  3. Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic

    Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient

  4. Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

    HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases,

  5. Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results

    HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initial data presented October 17, 2019. Further data due 2020.
Inarigivir and Vemlidy
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)
Phase 1 data to be presented at ASCO May 29 - June 2, 2020.
SB 11285 (ASCO)
Solid tumors
Development discontinued due to safety concerns (patient death).
Inarigivir - (CATALYST 1 and CATALYST 2)
Hepatitis B (HBV)

Latest News

  1. Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

    HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and

  2. Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results

    Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche's Tecentriq® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I and STING agonists

  3. Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic

    Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient

  4. Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

    HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases,

  5. Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results

    HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and

  6. Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV

    Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost structure to fund operations into late 2022

  7. Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program

    HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  8. Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019

    HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  9. Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285

    HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  10. Spring Bank Announces Investor Conference Presentations for the Remainder of 2019

    HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  11. Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update

    HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  12. Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY

    HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  13. Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank's STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting

    HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  14. Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance

    Significant investment demonstrates confidence in Spring Bank's novel development programs Extends Spring Bank's cash runway beyond the end of 2021 Accelerates HBV antisense and STING antagonist development